Lexaria Bioscience (LEXX) Receivables (2010 - 2026)

Lexaria Bioscience has disclosed Receivables across 17 years of filings, most recently posting $42029.0 for Q1 2026.

• Receivables for Q1 2026 came in at $42029.0, down 89.36% year-over-year; the trailing twelve-month figure through Feb 2026 was $42029.0 (down 89.36% YoY), and the FY2025 annual result was $368358.0, up 138.45% from the prior year.
• Receivables came in at $42029.0 for Q1 2026 at Lexaria Bioscience, down from $152057.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $583290.0 in Q4 2023 to a low of $42029.0 in Q1 2026.
• The 5-year median for Receivables is $272020.0 (2024), against an average of $279268.5.
• Across the five-year window, Receivables jumped 189.91% in 2024 and slumped 89.36% in 2026, its largest moves.
• Lexaria Bioscience's Receivables stood at $286322.0 in 2022, then jumped by 103.72% to $583290.0 in 2023, then tumbled by 43.85% to $327505.0 in 2024, then slumped by 53.57% to $152057.0 in 2025, then tumbled by 72.36% to $42029.0 in 2026.
• The last three Receivables figures came in at $42029.0 (Q1 2026), $152057.0 (Q4 2025), and $368358.0 (Q3 2025), per Business Quant data.